PRMT5 and prostate cancer: A competitive peptide (PUBLISH), originated from the minimal interaction domain in FUBP1 mediating PRMT5-FUBP1 interaction, effectively blocked PRMT5-mediated FUBP1 methylation and successfully suppressed the development of prostate cancer.